Expertise in
7
conditions

Dr. Adekunle O. Odunsi

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Elm And Carlton Streets, 
Buffalo, NY 
Accepting New Patients
Expertise in
7
conditions
Elm And Carlton Streets, 
Buffalo, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adekunle Odunsi is a Gynecologic Oncologist and an Oncologist in Buffalo, New York. Dr. Odunsi is highly rated in 7 conditions, according to our data. His top areas of expertise are Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Desmoplastic Small Round Cell Tumor, and Ovarian Cancer. Dr. Odunsi is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NY
Languages Spoken
English
Spanish
Yoruba
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

Elm And Carlton Streets, Buffalo, NY 14263

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: NC762
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Enrollment Status: Completed
Publish Date: October 04, 2023
Intervention Type: Biological
Study Phase: Phase 2
3D-PREDICT REGISTRY: 3D Prediction of Patient-specific Response Using Ex Vivo Interrogation of Live Cells From Tumors
3D-PREDICT REGISTRY: 3D Prediction of Patient-specific Response Using Ex Vivo Interrogation of Live Cells From Tumors
Enrollment Status: Unknown
Publish Date: March 24, 2023
Intervention Type: Diagnostic test
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
Enrollment Status: Unknown
Publish Date: September 19, 2019
Intervention Type: Biological
Study Drug: NKR-2 Cells
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

8 Total Publications

Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Journal: Journal for immunotherapy of cancer
Published: October 16, 2020
Similar Doctors
Francisco J. Hernandez-Ilizaliturri
Expertise in
28
conditions
Dr. Francisco J. Hernandez-Ilizaliturri
Oncology
Expertise in
28
conditions
Dr. Francisco J. Hernandez-Ilizaliturri
Oncology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (1.5 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francisco Hernandez-Ilizaliturri is an Oncologist in Buffalo, New York. Dr. Hernandez-Ilizaliturri is highly rated in 28 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Gastrostomy.

Expertise in
11
conditions
Dr. Karen Mclean
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
11
conditions
Dr. Karen Mclean
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Roswell Park Cancer Institute

Elm And Carlton St, 
Buffalo, NY 
 (1.5 miles away)
716-845-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Karen Mclean is a Gynecologic Oncologist and an Oncologist in Buffalo, New York. Dr. Mclean is highly rated in 11 conditions, according to our data. Her top areas of expertise are Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Endometrial Cancer, Hernia Surgery, and Bladder Reconstruction. Dr. Mclean is currently accepting new patients.

Expertise in
17
conditions
Dr. Peter J. Frederick
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
17
conditions
Dr. Peter J. Frederick
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Rpci Oncology, PC

21 Porter Ave, 
Jamestown, NY 
 (59.1 miles away)
716-664-1909
Languages Spoken:
English
See accepted insurances

Peter Frederick is a Gynecologic Oncologist and an Oncologist in Jamestown, New York. Dr. Frederick is highly rated in 17 conditions, according to our data. His top areas of expertise are Endometrial Cancer, Neonatal Ovarian Cyst, Ovarian Cysts, Oophorectomy, and Hysterectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Odunsi's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile